Multiple Sclerosis News and Research RSS Feed - Multiple Sclerosis News and Research

Multiple sclerosis (MS) is a severe autoimmune disease of the central nervous system that affects the brain and spinal cord, causing problems with muscle movement, balance and vision.

In MS, the protein coating called myelin, which protects nerves and helps electrical signals travel from the brain to the rest of the body, is damaged. The immune system, which usually fights infection, mistakes myelin for a foreign body and attacks it, stripping it from around the nerves. Exactly what causes this abnormal immune response is unclear, but research suggests a combination of both genetic and environmental factors.

The damaged myelin disrupts the transfer of nerve signals which may slow down, become distorted or stop altogether. This can cause severe symptoms ranging from vision loss through to muscle stiffness, loss of control over muscle movement, difficulties with balance and poor co-ordination.

Around 100,000 people in the UK have MS and it affects about three times as many women as men. The usual age at which diagnosis occurs is around 30, however, symptoms often first develop between the ages of 15 and 45.

Currently, there is no cure for MS but therapeutic approaches such as physiotherapy and steroid injections are used to manage the condition and ease symptoms.
Multiple Sclerosis Foundation launches 'Orange 4 MSF' campaign to promote MS awareness

Multiple Sclerosis Foundation launches 'Orange 4 MSF' campaign to promote MS awareness

The Multiple Sclerosis Foundation will officially launch their "Orange 4 MSF" campaign on Monday, February 16th to promote MS awareness. Since orange is the official color of awareness, MSF would like the public to show their support by taking a selfie with an orange and then posting it on social media with #orange4msf. [More]
Biotech experts to establish ethical guidelines in cellular biotechnology at BEINGS 2015

Biotech experts to establish ethical guidelines in cellular biotechnology at BEINGS 2015

In May 2015 Atlanta will host Biotechnology and the Ethical Imagination: A Global Summit (BEINGS), an international summit drawing together the world's thought leaders on the highly debated issues of cellular biotechnology. [More]
Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants more effective than mitoxantrone drug for people with severe multiple sclerosis

Stem cell transplants may be more effective than the drug mitoxantrone for people with severe cases of multiple sclerosis (MS), according to a new study published in the February 11, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Researchers create new intraoperative probe for detecting cancer cells

Researchers create new intraoperative probe for detecting cancer cells

Brain cancer patients may live longer thanks to a new cancer-detection method developed by researchers at the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and the MUHC, and Polytechnique Montréal. [More]
Epigem contribute to PhD research into Multiple Sclerosis

Epigem contribute to PhD research into Multiple Sclerosis

Epigem, a high-tech British micro engineering company, is supporting research into Multiple Sclerosis (MS) with a new PhD programme to create a novel drug screening platform. This will accelerate the production of MS models and pre-clinical drug development, in order to understand better the disease process and its periods of remission. [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Mercury associated with autoimmunity among women of childbearing age

Mercury associated with autoimmunity among women of childbearing age

One of the greatest risk factors for autoimmunity among women of childbearing age may be associated with exposure to mercury such as through seafood, a new University of Michigan study says. [More]
Researchers document pathological progress of multiple sclerosis

Researchers document pathological progress of multiple sclerosis

The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play. [More]
Diplomat to dispense FDA-approved IBRANCE (palbociclib) to treat metastatic breast cancer

Diplomat to dispense FDA-approved IBRANCE (palbociclib) to treat metastatic breast cancer

Diplomat Pharmacy, Inc., the nation's largest independent specialty pharmacy, announced today it will dispense Pfizer's new breakthrough medication, IBRANCE (palbociclib), starting tomorrow, Feb. 5. [More]
Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. [More]
EyeBrain raises €1.3 million ($1.47 million) through crowdfunding

EyeBrain raises €1.3 million ($1.47 million) through crowdfunding

EyeBrain, a company that develops markers of cerebral function for neurological and psychiatric disorders and diseases, today announces the conclusion of a new round of funding. A total of €1.3 million ($1.47 million) has been raised with the support of EyeBrain’s shareholders, the Fonds Régional de Co-Investissement d’Ile-de-France (FRCI, regional joint investment fund for the Ile-de-France or Greater Paris area) and the Anaxago crowdfunding platform. [More]
Accelerated Cure Project for MS launches nationwide initiative to fuel multiple sclerosis research

Accelerated Cure Project for MS launches nationwide initiative to fuel multiple sclerosis research

The Accelerated Cure Project for Multiple Sclerosis today launches iConquerMS, the nationwide initiative by and for individuals living with multiple sclerosis who recognize the power of their health data and insights and want to harness that power to fuel research. [More]
People's perceptions of cost of drug may affect how much they benefit from it

People's perceptions of cost of drug may affect how much they benefit from it

People's perceptions of the cost of a drug may affect how much they benefit from the drug, even when they are receiving only a placebo, according to a new study of people with Parkinson's disease published in the January 28, 2015 online issue of Neurology®, the medical journal of the American Academy of Neurology. [More]
Promising results for stem cell therapy in MS

Promising results for stem cell therapy in MS

Preliminary findings suggest that nonmyeloablative haematopoietic stem cell transplantation may arrest, or even reverse, the progress of disease among patients with relapsing–remitting multiple sclerosis. [More]
Scientists identify new molecular pathway that controls axonal degeneration following injury

Scientists identify new molecular pathway that controls axonal degeneration following injury

Axons connect neurons with each other to form the neural networks that underpin the vital functions of perception, motility, cognition, and memory. In many neurodegenerative disorders, from traumatic injury or toxic damage to diseases such as Alzheimer's or Parkinson's disease, axonal degeneration represents an essential pathological feature. [More]
New discovery may help doctors develop better treatments for brain, spinal cord injuries

New discovery may help doctors develop better treatments for brain, spinal cord injuries

In a discovery that could dramatically affect the treatment of brain and spinal cord injuries, researchers have identified a previously unknown, beneficial immune response that occurs after injury to the central nervous system. [More]
Scientists identify gene that helps regulate development of central nervous system

Scientists identify gene that helps regulate development of central nervous system

Scientists have identified a gene that helps regulate how well nerves of the central nervous system are insulated, researchers at Washington University School of Medicine in St. Louis report. [More]
USC neuroscientists find potential prevention for Alzheimer's disease

USC neuroscientists find potential prevention for Alzheimer's disease

University of Southern California neuroscientists may have unlocked another puzzle to preventing risks that can lead to Alzheimer's disease. Researchers at Keck Medicine of USC used high-resolution imaging of the living human brain to show for the first time that the brain's protective blood barrier becomes leaky with age, starting at the hippocampus, a critical learning and memory center that is damaged by Alzheimer's disease. [More]
New article provides insight into cognitive fatigue in people with multiple sclerosis

New article provides insight into cognitive fatigue in people with multiple sclerosis

Kessler Foundation researchers have authored a new article that provides insight into the factors that contribute to cognitive fatigue in individuals with multiple sclerosis (MS). The article, "Subjective cognitive fatigue in MS depends on task length," was epublished ahead of print on October 27 in Frontiers in Neurology. [More]
Two new drug compounds appear to be effective in treating endometriosis

Two new drug compounds appear to be effective in treating endometriosis

Two new drug compounds - one of which has already proven useful in a mouse model of multiple sclerosis - appear to be effective in treating endometriosis, a disorder that, like MS, is driven by estrogen and inflammation, scientists report in Science Translational Medicine. [More]